Hochmair, Maximilian Johannes
122  results:
Search for persons X
?
7

Selpercatinib in RET fusion-positive non-small-cell lung ca..:

Illini, Oliver ; Hochmair, Maximilian Johannes ; Fabikan, Hannah...
Therapeutic Advances in Medical Oncology.  13 (2021)  - p. 175883592110196 , 2021
 
?
 
?
11

Nintedanib plus Docetaxel after Immune Checkpoint Inhibitor..:

Hochmair, Maximilian Johannes ; Kolb, Rainer ; Wurm, Robert..
Case Reports in Oncology. -15 (2022), p. 138-148. -Case Rep Oncol. - 1662-6575.  , 2022
 
?
15

Selpercatinib in RET fusion-positive non-small-cell lung ca..:

Illini, Oliver ; Hochmair, Maximilian Johannes ; Fabikan, Hannah...
Illini , O , Hochmair , M J , Fabikan , H , Weinlinger , C , Tufman , A , Swalduz , A , Lamberg , K , Hashemi , S M S , Huemer , F , Vikström , A , Wermke , M , Absenger , G , Addeo , A , Banerji , S , Calles , A , Clarke , S , di Maio , M , Durand , A , Duruisseaux , M , Itchins , M , Kääränien , O-S , Krenn , F , Laack , E , de Langen , A J , Mohorcic , K , Pall , G , Passaro , A , Prager , G , Rittmeyer , A , Rothenstein , J , Schumacher , M , Wöll , E & Valipour , A 2021 , ' Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program ' , Therapeutic Advances in Medical Oncology , vol. 13 . https://doi.org/10.1177/17588359211019675.  , 2021
 
1-15